SCHEMBL177455

SCHEMBL177455

Cc1ccc(OBOc2ccc(C)c(Cl)c2)cc1Cl

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.45
DRD2 P14416 1/20 0.41
DRD4 P21917 1/20 0.41
DRD3 P35462 1/20 0.41
SLC6A4 P31645 2/20 0.41
HTR2A P28223 1/20 0.41
KCNH2 Q12809 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.40
LMNA P02545 2/20 0.40
RAPGEF4 Q8WZA2 1/20 0.36
MAPT P10636 6/20 0.34
HPGD P15428 2/20 0.34
NPC1 O15118 2/20 0.34
RAB9A P51151 2/20 0.34
CYP2D6 P10635 1/20 0.34
SLC6A2 P23975 1/20 0.34
SLC6A3 Q01959 1/20 0.34
KDM4E B2RXH2 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2C9 P11712 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19886444 0.83 CYP3A4 (0.42) CYP3A4DRD2DRD4DRD3SLC6A4
SCHEMBL177406 0.83 MCL1 (0.49) SLC6A4HTR2AKCNH2SMN1; SMN2MAPT
SCHEMBL14396803 0.79 HTR2A (0.51) CYP3A4DRD2DRD4DRD3SLC6A4
SCHEMBL177501 0.79 HSP90AA1 (0.47) CYP3A4SLC6A4HTR2AKCNH2SMN1; SMN2
SCHEMBL177356 0.79 TDP1 (0.44) DRD2DRD4DRD3SLC6A4HTR2A
SCHEMBL29804592 0.79 TDP1 (0.44) DRD2DRD4DRD3SLC6A4HTR2A
SCHEMBL2205828 0.77 MAPT (0.50) CYP3A4DRD2DRD4DRD3SLC6A4
SCHEMBL3755105 0.76 CYP3A4 (0.46) CYP3A4DRD2DRD4DRD3SLC6A4
SCHEMBL177471 0.75 CA12 (0.43) SLC6A4SMN1; SMN2MAPTHPGDNPC1
SCHEMBL25798448 0.74 CYP3A4 (0.45) CYP3A4DRD2DRD4DRD3SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024129780-A1 BENZIMIDAZOLE DERIVATIVES AS GPX4 INHIBITORS SONATA THERAPEUTICS, INC. (US) 2024-06-20 WO disclosed
CN-118184710-A Organic electroluminescent material and device 环球展览公司 2024-06-14 CN disclosed
CN-118084982-A Organic electroluminescent material and device 环球展览公司 2024-05-28 CN disclosed
CN-118084983-A Organic electroluminescent material and device 环球展览公司 2024-05-28 CN disclosed
CN-117801024-A Organic electroluminescent material and device 环球展览公司 2024-04-02 CN disclosed
CN-107522747-B Organic electroluminescent material and device 环球展览公司 2024-03-05 CN disclosed
CN-107522749-B Organic electroluminescent material and device 环球展览公司 2024-03-05 CN disclosed
CN-107522748-B Organic electroluminescent material and device 环球展览公司 2024-01-09 CN disclosed
CN-116568677-A piperidin-1-yl-N-pyridin-3-yl-2-oxoacetamide derivatives useful for the treatment of MTAP deficiency and/or MTA accumulating cancers 探戈医药股份有限公司 2023-08-08 CN disclosed
CN-116323557-A Cyclobutylamide monoacylglycerol lipase modulators 詹森药业有限公司 2023-06-23 CN disclosed
US-8329675-B2 Inhibitors of fatty acid amide hydrolase INFINITY PHARMACEUTICALS, INC. (US) 2012-12-11 US disclosed
EP-2404607-A1 Boronic acids and esters as inhibitors of fatty acid amide hydrolase Infinity Pharmaceuticals, Inc. (US) 2012-01-11 EP disclosed
EP-2399585-A1 Boronic acids and esters as inhibitors of fatty acid amide hydrolase Infinity Pharmaceuticals, Inc. (US) 2011-12-28 EP disclosed
EP-2399584-A1 Boronic acids and esters as inhibitors of fatty acid amide hydrolase Infinity Pharmaceuticals, Inc. (US) 2011-12-28 EP disclosed
US-20110230440-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE ADAMS JULIAN 2011-09-22 US disclosed
US-20110224171-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY DISCOVERY, INC. 2011-09-15 US disclosed
EP-2073816-B1 BORONIC ACIDS AND ESTERS AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS INC (US) 2011-09-14 EP disclosed
US-7645773-B2 Thiazoles as inhibitors of 11β-hydroxysteroid dehydrogenase HOFFMANN-LA ROCHE INC. (US) 2010-01-12 US disclosed
EP-2073816-A2 INHIBITORS OF FATTY ACID AMIDE HYDROLASE Infinity Pharmaceuticals, Inc. (US) 2009-07-01 EP disclosed
WO-2008063300-A2 BORONIC ACIDS AND ESTERS AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. (US) 2008-05-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224171-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, ASAH1 CYP3A4 1007/4885DRD2 2253/4885DRD4 3365/4885
US-20110230440-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, ASAH1 CYP3A4 1007/4885DRD2 2253/4885DRD4 3365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.